Intuitive Surgical
Corporate brand
UnclaimedA medical-device company known for robotic-assisted minimally invasive surgery systems, especially the da Vinci platform.
Last updated October 11, 2026
AI crawler reads
No AI crawler has read this profile yet.
Overview
Intuitive Surgical is a United States medical-device and biotechnology company that develops, manufactures, and markets robotic systems, instruments, visualization technologies, and related services for minimally invasive surgery. Its best-known product is the da Vinci Surgical System, a surgeon-controlled platform that translates hand movements at a console into precise movements by instruments positioned inside the patient. The system is designed to support laparoscopic and other minimally invasive procedures rather than to operate autonomously. The company grew out of research conducted at SRI International in the late 1980s and early 1990s. That work attracted interest from the U.S. National Institutes of Health and the Defense Advanced Research Projects Agency, partly because remote surgery could have military and battlefield applications. Frederic Moll, then associated with Guidant, became interested in the technology in 1994. Together with John Freund and Robert Younge, Moll helped secure an option to acquire relevant intellectual property, formed Intuitive Surgical Devices in 1995, and raised early venture capital from investors including Mayfield Fund, Sierra Ventures, and Morgan Stanley. Intuitive refined the SRI technology through a succession of prototypes whose names drew on Leonardo da Vinci. The company began marketing the da Vinci system in Europe in 1999 and received U.S. Food and Drug Administration clearance for general laparoscopic surgery in 2000. Subsequent clearances expanded the platform's use into areas including prostate surgery, thoracic surgery, cardiac procedures performed with adjunctive incisions, and gynecologic surgery. The platform has been particularly associated with prostatectomy, gynecologic procedures, cardiac valve repair, and other operations in which surgeons seek enhanced visualization, instrument articulation, and ergonomic control. The company's early competitive environment included Computer Motion, maker of the ZEUS robotic surgical system. A patent dispute between the companies created uncertainty before Intuitive's public offering. The dispute ended when the companies merged in 2003, after which the ZEUS platform was gradually discontinued in favor of da Vinci. Intuitive went public in 2000, raising approximately $46 million, and subsequently developed a business model combining capital equipment placements with recurring revenue from instruments, accessories, service contracts, and related support. Intuitive's commercial position is built around a platform ecosystem. Hospitals acquire or lease systems, while each procedure generally requires specialized instruments and accessories with usage limits. The company also provides training, maintenance, clinical support, and digital or visualization capabilities. This recurring model has supported expansion as the installed base and procedure volume have grown. Publicly described company data recorded 6,730 da Vinci systems installed worldwide at the end of 2021, including systems in the United States, Europe, Asia, and other regions. The company remains focused on robotic-assisted surgery and adjacent technologies rather than operating hospitals or directly providing clinical care. Its growth has also generated scrutiny concerning system cost, evidence of clinical benefit, surgeon training, patient injuries, replacement parts, aftermarket practices, and the competitive effects of its market position. Intuitive is listed on the Nasdaq under ISRG and has been included in major U.S. equity indexes, including the Nasdaq-100, S&P 100, and S&P 500.
History
The technical foundation of Intuitive Surgical's business originated in research at SRI International during the late 1980s. Researchers including Ajit Shah and Gary Guthart worked on a robotic surgical system intended to improve a surgeon's ability to perform minimally invasive procedures. In 1990, SRI received funding from the National Institutes of Health. The project also attracted interest from the Defense Advanced Research Projects Agency, which considered whether remote surgical control could help treat wounded soldiers without requiring the surgeon to be physically present at the battlefield. Frederic Moll became interested in the SRI system in 1994 while working at Guidant. After Guidant declined to support the project, Moll connected with John Freund, a former Acuson executive. Freund negotiated an option concerning SRI's intellectual property, and in 1995 he, Moll, and Robert Younge established Intuitive Surgical Devices. The founders prepared a business plan and obtained initial financing from venture investors, including Mayfield Fund, Sierra Ventures, and Morgan Stanley. The company converted the research platform into a commercial product through iterative prototypes. Early versions were given Leonardo-themed names, including Lenny, Leonardo, and Mona. The final commercial platform became known as the da Vinci Surgical System. Intuitive began marketing the system in Europe in 1999 while seeking U.S. regulatory clearance. In 2000, the company completed an initial public offering that raised approximately $46 million, and the FDA cleared da Vinci for general laparoscopic surgery. A further clearance for prostate surgery followed in 2001, with later regulatory expansions covering thoracic, selected cardiac, and gynecologic procedures. Intuitive's early market was shaped by a dispute with Computer Motion, which had developed the ZEUS robotic surgical system. Computer Motion entered the field before Intuitive, and the two companies became involved in patent litigation. Although ZEUS had European approval, it had not obtained U.S. FDA approval for a procedure when da Vinci first received its U.S. clearance. The litigation and regulatory uncertainty affected both companies' expansion. In 2003, Intuitive and Computer Motion agreed to merge, ending the dispute. The ZEUS system was subsequently phased out as Intuitive concentrated the market around da Vinci. The company's growth depended on both system placements and recurring procedure-related revenue. Public descriptions of its development noted an increase from 60 systems sold in 2002 to 431 in 2014, while annual procedures rose from fewer than 1,000 in 2002 to approximately 540,000 in 2014. The da Vinci model also created an installed-base business: hospitals paid for the system and associated service, while instruments and accessories were purchased for individual procedures. This structure helped Intuitive scale as more hospitals trained surgeons and incorporated robotic assistance into urologic, gynecologic, thoracic, cardiac, and general surgical practices. The platform has remained surgeon-operated. A physician sits at a console and controls instruments attached to a patient-side cart, with the system providing magnified visualization and articulated instrument movement. Intuitive has continued to develop the hardware, instruments, visualization, stapling, energy, training, and service components surrounding the core platform. Its position has also brought criticism. Hospitals and commentators have questioned the high acquisition and operating costs, the evidence needed to justify robotic surgery in particular procedures, and whether hospitals can recover the expense of the systems. The company has faced product-liability, securities, patent, antitrust, and aftermarket-repair litigation, including a 2018 shareholder settlement and disputes over access to replacement parts. Intuitive Surgical is headquartered in Sunnyvale, California, and trades on the Nasdaq under ISRG. It is included in prominent U.S. market indexes. By the end of 2021, the publicly documented installed base comprised 6,730 da Vinci systems worldwide, with the largest concentration in the United States and additional systems across Europe, Asia, and other markets. The company continues to operate as a medical-technology manufacturer and service provider rather than as a healthcare provider.
- 2021
Documented global installed base reaches 6,730 systems
[1]Publicly cited company information reported 6,730 installed da Vinci systems worldwide as of December 31, 2021.
- 2018
Shareholder litigation settlement
[1]Intuitive agreed to a $43 million settlement in shareholder class actions concerning alleged disclosure failures related to da Vinci injuries.
- 2009
da Vinci Si introduced
[1]The da Vinci Si generation was released, representing a major iteration of the company's surgical-robotics platform.
- 2003
Merger with Computer Motion
[1]Intuitive merged with its robotic-surgery rival Computer Motion, ending patent litigation and leading to the retirement of the ZEUS platform in favor of da Vinci.
- 2001
Prostate-surgery clearance
[1]The FDA cleared the da Vinci system for prostate surgery, expanding its U.S. clinical application.
- 2000
IPO and first U.S. FDA clearance
[1]Intuitive raised approximately $46 million in its initial public offering, and the FDA cleared da Vinci for general laparoscopic surgery.
- 1999
European marketing begins
[1]Intuitive began marketing the da Vinci Surgical System in Europe while awaiting U.S. regulatory authorization.
- 1997
Prototype reaches testing stage
[1]The company prepared an early da Vinci-related prototype for testing after developing several Leonardo-themed system versions.
- 1995
Intuitive Surgical Devices is founded
[1]Frederic Moll, John Freund, and Robert Younge established the company and secured an option concerning SRI's surgical-robotics intellectual property.
- 1990
SRI receives NIH support for robotic surgery research
[1]Research at SRI International received National Institutes of Health funding, supporting development of the robotic surgical technology that later informed da Vinci.
Products and positioning
A global specialist in robotic-assisted minimally invasive surgery, combining capital equipment with procedure-linked instruments, visualization, training, and service support.
Robotic-assisted surgery platform · 1999
da Vinci Surgical System
The da Vinci platform is a surgeon-controlled robotic system for minimally invasive procedures. It generally combines a surgeon console, a patient-side cart, and a high-resolution visualization system. The platform translates the surgeon's console movements into instrument movements inside the patient and is used across specialties including urology, gynecology, thoracic surgery, cardiac procedures, and general surgery. It is supported by procedure-specific instruments, accessories, training, and service contracts.
Surgical-robot generation · 2009
da Vinci Si
The da Vinci Si was a major generation of the company's robotic surgery system, introduced in 2009. It retained the console-and-patient-cart architecture while providing an updated platform for surgeon-controlled minimally invasive procedures.
Procedure consumables
da Vinci surgical instruments and accessories
Intuitive supplies specialized instruments and accessories used with da Vinci systems. These products are designed for different surgical tasks and procedures and form an important recurring component of the company's business model because instruments are used and replaced during ongoing clinical activity.
Surgical visualization
da Vinci visualization systems
Visualization components provide the surgeon with magnified, stereoscopic views of the operative field from the console. They are integrated into the da Vinci platform and support the system's minimally invasive workflow.
Controversies
2024
Sultzer product-liability case dismissed
A product-liability plaintiff alleged that an electrical defect caused an arc through a patient's spine and resulted in death. The plaintiff agreed to drop the case in July 2024.
2021
Aftermarket replacement-parts antitrust allegations
Rebotix Repair alleged that Intuitive abused a monopolistic position by restricting competition in replacement parts and overcharging hospitals. Related claims were later brought by healthcare organizations, and the Rebotix matter settled in 2022.
2018
Shareholder disclosure litigation
Shareholders alleged that Intuitive failed to disclose injuries associated with da Vinci systems, violating federal securities laws. The company settled the class actions for $43 million.
Brand decisions
2003
Merge with Computer MotionM&ABackground
Intuitive and Computer Motion were competing in robotic surgery and were involved in patent litigation. Computer Motion marketed the ZEUS system, while Intuitive's da Vinci system had obtained U.S. FDA clearance.
Action taken
The companies agreed to merge, ending the litigation and consolidating the principal competing platforms under Intuitive's business.
Aftermath
The ZEUS system was eventually phased out, and Intuitive concentrated commercial development on da Vinci.
2000
Commercial expansion of the da Vinci platformProduct launchBackground
After European marketing began in 1999, Intuitive sought to establish the system in the U.S. minimally invasive surgery market.
Action taken
The company completed its initial public offering and expanded the da Vinci platform following FDA clearance for general laparoscopic surgery.
Aftermath
Later clearances enabled use in additional specialties, including prostate, thoracic, cardiac, and gynecologic procedures.
Recent events
- Unconfirmed
Reported
Intuitive Surgical discloses settlement[3]
Intuitive Surgical disclosed a settlement; the headline provides no further details about the settlement.
- Unconfirmed
Reported
Intuitive Surgical deepens ties with Shanghai[4]
China Daily reported that Intuitive Surgical, described as a biotech company, is deepening its ties with Shanghai; the available report text (headline only) does not specify the concrete form or date of the cooperation.
Reported
Rutland Regional Medical Center debuts Intuitive Surgical da Vinci 5 surgical robot[5]
Rutland Regional Medical Center (RRMC) publicly debuted the Intuitive Surgical da Vinci 5 surgical robot at a community event at the Paramount Theatre on Saturday, after the robot was delivered to the hospital the prior week. Intuitive Surgical partnered with RRMC to bring two traveling demonstration machines, one running a virtual simulation and one offering a physical demonstration. The hospital said general surgeons are being trained first, followed by OB-GYN surgeons and urologists, and that the robot will begin being used in surgical cases the first week of November. RRMC said it is the first independent healthcare system in Vermont with its own robot and one of only two da Vinci 5s in the state.
Weekdays and relative dates follow the original report; their exact calendar dates have not been verified.
Reported
Intuitive Surgical launches its first venture capital fund[6]
Intuitive Surgical launched its first venture capital fund, Intuitive Ventures, with an inaugural $100 million fund focused on early-stage companies in minimally invasive care and related fields.
Sources6 sources
Cite this profile: Cite the canonical profile. /brand-wiki/intuitive-surgical · Editorial policy · How profiles are compiled